Status:
COMPLETED
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
Lead Sponsor:
Xention Ltd
Collaborating Sponsors:
Ario Pharma Ltd
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD). The effect...
Eligibility Criteria
Inclusion
- Male/female subjects aged 40 or over with COPD
Exclusion
- Clinically significant medical history
- Abnormal laboratory results, ECGs or vital signs
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT02233686
Start Date
February 1 2014
End Date
February 1 2015
Last Update
July 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medicines Evaluation Unit
Manchester, United Kingdom, M23 9QZ